Two office buildings in Collegeville have sold to Audubon-based Globus Medical for $6.2 million, marking an 81 percent drop ...

It has been about a month since the last earnings report for Nevro (NVRO). Shares have lost about 8.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Thornal will join the orthopedics company as group president for global businesses and the Americas, a newly created position ...

A month has gone by since the last earnings report for Nevro (NVRO). Shares have added about 15.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

Nevro is advancing its application to the FDA for its spinal cord stimulation treatment of PDN with a potential launch later this year. Nevro is guiding for a strong recovery in 2021, which is ...

In terms of headline numbers, Nevro's performance for the quarter was mixed. It earned $102.3 million in revenue, nearly double the $56.4 million it booked in the same period a year ago.

Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficient marketing, and internationalization efforts ...

Analysts' ratings for Nevro (NYSE:NVRO) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below offers a condensed view of their recent ratings, showcasing ...

The market expects Nevro (NVRO) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2020. This widely-known consensus outlook is ...